Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

78.7%

48 terminated/withdrawn out of 61 trials

Success Rate

7.7%

-78.8% vs industry average

Late-Stage Pipeline

46%

28 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

5 recruiting2 with results28 terminated20 withdrawn

Enrollment Performance

Analytics

Phase 3

15(26.3%)

Phase 2

14(24.6%)

Phase 4

13(22.8%)

N/A

11(19.3%)

Phase 1

3(5.3%)

Early Phase 1

1(1.8%)

57Total

Phase 3(15)

Phase 2(14)

Phase 4(13)

N/A(11)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (61)

Showing 20 of 61 trials

NCT07430137Not ApplicableNot Yet Recruiting

Blink Reminders and Meibomian Gland Loss in Digital Screen Users

Role: lead

NCT05636579Phase 1Recruiting

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Role: lead

NCT05587205Phase 1Recruiting

Safety and Tolerability of EO2002

Role: lead

NCT07175311Recruiting

Vascular Changes Associated With Endophthalmitis.

Role: lead

NCT07095907Not ApplicableRecruiting

Post-surgical Functional Results in Patients With Epiretinal Membrane Undergoing Controlled Macular Detachment

Role: lead

NCT05736081Phase 4Completed

Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema

Role: lead

NCT00555594Phase 2Completed

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Role: lead

NCT00346814Phase 2Recruiting

Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Role: lead

NCT00496405Phase 4Withdrawn

Unilateral Bevacizumab for Bilateral Diabetic Macular Edema

Role: lead

NCT00418431Phase 2Withdrawn

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Role: lead

NCT00406172Phase 3Withdrawn

Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

Role: lead

NCT00347711Phase 3Withdrawn

Bevacizumab and Retinal Vascular Occlusions

Role: lead

NCT00417716Phase 3Withdrawn

Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

Role: lead

NCT00599820Phase 3Terminated

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Role: lead

NCT00567372Phase 4Withdrawn

POSTERIOR SUB-TENON'S Avastin

Role: lead

NCT00406744Phase 3Terminated

Efficacy of Retreatments With Intravitreal Bevacizumab

Role: lead

NCT00925886Not ApplicableTerminated

Use of Toric Intraocular Lens to Neutralize Keratometric Astigmatism

Role: lead

NCT00600236Phase 3Withdrawn

HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

Role: lead

NCT00403702Phase 2Withdrawn

Comparison High-density Silicone Oils in Retinal Detachment

Role: lead

NCT00417833Phase 2Terminated

Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

Role: lead